Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis


Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Standard Treatments for Chronic Hepatitis C in the HIV-Infected patient

for Health Care Providers

Table 10. Standard Treatments for Chronic Hepatitis C in the HIV-Infected patient

Back to HIV Coinfection Recommendations

(Trade Name)
Recommended DoseMajor Adverse Effects*
*Adverse effects included are limited to those reported in highest frequency in placebo-controlled studies, or are of sufficient severity to warrant discontinuation of therapy and/or treatment of the adverse effect(s). Consult other references for complete listing of reported adverse effects.
Peginterferon alfa 2b-12 kD (PEG-IntronR)Weekly dose of 1.5 µg/kg SCFlu-like symptoms
Bone marrow suppression
Peginterferon a-2a-40 kD (PegasysR) Weekly dose of 180 µg/kg SCDecrease in absolute CD4 count but not CD4%
Aggravation of autoimmune disorders
Neuropsychiatric symptoms
Acute cardiac and renal failure
Interstitial pulmonary fibrosis
More frequent injection site reactions and neutropenia with pegylated formulations of interferon than standard interferon
Ribavirin (CopegusR, RebetolR) Genotype 1: 1,000 mg daily po, if patient weight <=75 kg; 1,200 mg daily po if patient weight >75 kgHemolytic anemia
Significant teratogen
Genotype 2,3: 800 mg daily poShortness of breath
GI side-effects